<DOC>
	<DOCNO>NCT02534129</DOCNO>
	<brief_summary>Phase II trial silibin contain cream , Difinsa53 determine efficacy delaying , ameliorate , prevent radiation dermatitis patient breast cancer undergo whole breast radiation .</brief_summary>
	<brief_title>Topical Use Difinsa53™ Prevent Radiation Dermatitis</brief_title>
	<detailed_description>The propose study seek evaluate efficacy DIFINISA53™ , safe silibin-based skin cream , prevent radiation dermatitis ( RD ) compare counter ointment , Aquaphor , woman undergo radiation therapy breast cancer follow lumpectomy mastectomy surgery . Presently know fully effective topical protectant RD consensus among radiation oncologist best treat RD . This study seek identify effective option patient receive radiation therapy . Each participant apply DIFINISA53™ cream one area treat skin Aquaphor another area treat skin . Skin reaction evaluate use medical professional assessment , participant assessment , photographic assessment third party .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<criteria>Female patient 18 year old Pathologic diagnosis breast cancer require radiation therapy whole breast Able apply lotion treatment area least twice daily radiation course All surgical site heal No evidence infection No history sensitivity component Aquaphor Difensa53 Prior history radiation therapy ( RT ) site Known dermatologic condition affect skin radiation port Concurrent chemotherapy Skin infection radiation port History sensitivity Aquaphor Difensa53 component</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>dermatitis</keyword>
</DOC>